# PT-141 Research: The Bremelanotide Clinical and Preclinical Record > PT-141 research summarized: the RECONNECT Phase 3 trials, the fMRI mechanism study, the preclinical solicitation data, and the off-label male evidence. Every figure cited. What the literature genuinely establishes, what stays preclinical, and what is off-label — sorted and sourced. ## The short version Here is the PT-141 research record in one paragraph. Animal work in the early 2000s showed the peptide acts in the brain — it triggered erections in rats and primates and increased desire-driven behavior in female rats. Two large human trials (RECONNECT) in premenopausal women with low sexual desire met their goals, but the improvement over a dummy injection was small. A brain-scan study showed the desire effect lasting up to a day. Evidence in men, for erectile difficulty, is early-stage only. We separate the strong findings from the thin ones and cite each one. ## PT-141 for women: the approved HSDD indication The one approved use is the one with the strongest data. In RECONNECT — two identical Phase 3 randomized, double-blind, placebo-controlled trials enrolling 1267 premenopausal women with HSDD — bremelanotide 1.75 mg subcutaneous as-needed met both coprimary endpoints over 24 weeks: the integrated FSFI-desire score improved by +0.35 and the FSDS-DAO item-13 (distress about low desire) score fell by -0.33, both versus placebo, both at P<.001 [3]. A 52-week open-label extension (684 women) found the desire improvements were sustained with no new safety signals [4]. Mechanistically, the effect is central. In a randomized crossover functional-MRI study of 31 premenopausal women with HSDD, MC4R agonism significantly increased sexual desire for up to 24 hours and enhanced task-based brain processing of erotic stimuli, including amygdala-insula connectivity [5]. A 2025 conference abstract reported additional benefit on arousal and orgasm domains beyond the desire endpoint, though as an abstract it sits at a lower evidence tier than the peer-reviewed trials [11]. ## What the trials actually showed (modest but real) The PT-141 benefits in the approved population are real and statistically robust — and clinically modest. The headline numbers bear repeating because their size is the story: an integrated FSFI-desire gain of +0.35 and an FSDS-DAO item-13 distress reduction of -0.33 over placebo [3]. These are group-level differences on multi-point questionnaires, not transformations. Critical re-analyses have argued the effects on desire and distress, while significant, are small, and have questioned the clinical meaningfulness of the chosen outcome measures [6]. A 2025 comparative abstract set bremelanotide alongside flibanserin (the other approved HSDD medication) and testosterone therapy, contrasting their effect profiles [12]. The defensible summary: bremelanotide produces a measurable, reproducible, modest improvement in desire and desire-related distress in premenopausal women with HSDD — and reasonable readers disagree about how much that means. ## PT-141 for men: off-label and investigational only Use of PT-141 in men is off-label, and the evidence is early-phase. The compound's own origin is here: early development tested an intranasal formulation in men with erectile dysfunction and reported dose-dependent erectile responses, but that route was later discontinued for pharmacokinetic variability [1]. A 2024 sexual-medicine-clinic abstract described real-world, off-label use of bremelanotide in men with sexual dysfunction outside the approved female indication [13]. Development is ongoing, not established. In June 2024 the developer announced initiation of a Phase 2 study (about 50 patients) of bremelanotide co-administered with a PDE-5 inhibitor for erectile dysfunction in men who do not respond to PDE-5 inhibitors alone, with a co-formulation program [14]. That is a pipeline statement from a corporate press release, not a peer-reviewed outcome. Note also that one older (2008) erectile-dysfunction study received a 2023 Expression of Concern — a formal editorial notice that a paper's integrity is in question — so its findings should be treated as disputed. ## The preclinical foundation and a careful negative finding The animal record is where the central mechanism was first pinned down. Systemic PT-141 produced erections in rats and nonhuman primates and increased c-Fos (a marker of neuronal activation) in the hypothalamus, consistent with a central site of action [1]. In a landmark female-rat study, PT-141 selectively facilitated solicitational behavior without affecting lordosis, pacing, or general motor activity — evidence that central melanocortin systems regulate appetitive female sexual behavior [2]. Not every preclinical result is confirmatory, and the honest record includes the misses. A 2025 study in female Syrian hamsters found MC3R/MC4R mRNA concentrated in ventral tegmental area dopamine neurons, but neither low- nor high-dose bremelanotide changed melanocortin-receptor mRNA in the mesolimbic dopamine system, and the drug did not enhance sexual reward in a conditioned-place-preference test — a nuanced negative finding suggesting it may not act through the classic VTA reward circuit [10]. We report it because a complete record reports the findings that complicate the picture. ## Field reports (not clinical data) **FIELD TRANSMISSION — unverified community reports, not the clinical literature.** The notes below summarize patterns people describe online when discussing PT-141. They are reported experiences, not evidence and not advice, none of it is attributed to any journal or study, and nothing here should be read as a protocol or an encouragement to self-administer. Verified findings live in the cited sections above; these do not. What researchers commonly describe in informal discussion: a fast-onset warm "flush" sensation; nausea that tends to arrive within the first hour and that some find limits use; a sense of spontaneous arousal rather than a purely physical effect; and a frequently-passed-around warning that repeated frequent use can cause temporary skin or gum darkening. Anecdotal off-label male use is also widely discussed despite the lack of approval for that purpose. Again: these are community reports only, they vary from person to person, and they are categorically separate from the trial and label data this site cites. --- A chrome-bright console reading of the bremelanotide record — the one approved indication, the modest effect, and the honest tolerability profile logged to source, with the community field reports quarantined apart; not a clinic, not a vendor, not a prescription.